Abstract | BACKGROUND: OBJECTIVE: The objective of this study was to evaluate whether folate fortification has been associated with a higher incidence of adverse outcomes in children with ALL. METHODS: In a retrospective, population-based study, using data from the Pediatric Oncology Group of Ontario (POGO), Ontario, Canada, and the WHO, we examined yearly and population-adjusted mortality rates in Canada, the US, and several European countries. RESULTS: Our analysis demonstrates that there has been a decreasing trend in ALL mortality numbers and rates between 1999 and 2005 in the US and Canada, in a similar degree to those in European countries where folate fortification is not implemented. CONCLUSION: These data suggest that folate fortification does not appear to have caused an increase in therapeutic failures in children with ALL.
|
Authors | Deborah A Kennedy, Sandy Grupp, Mark Greenberg, Gideon Koren |
Journal | Paediatric drugs
(Paediatr Drugs)
Vol. 13
Issue 3
Pg. 193-6
(Jun 01 2011)
ISSN: 1179-2019 [Electronic] Switzerland |
PMID | 21366358
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Folic Acid Antagonists
- Folic Acid
- Methotrexate
|
Topics |
- Child
- Child, Preschool
- Databases, Factual
- Folic Acid
(adverse effects)
- Folic Acid Antagonists
(therapeutic use)
- Food, Fortified
(adverse effects)
- Humans
- Infant
- Infant, Newborn
- Methotrexate
(therapeutic use)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, mortality)
- Retrospective Studies
- Survival Analysis
- Treatment Failure
- World Health Organization
|